Address

MaRS Center, South Tower

101 College Street, Suite 300

Toronto, ON, M5G 1L7


Get in touch

Keeping Patients in Sight

We see new ways to deliver drugs

Ripple is a clinical stage ophthalmic therapeutics company focused on sustained drug delivery without the use of polymers or excipients. Our novel therapeutics provide for better outcomes for patients, easier management of care for physicians and lower costs for payors.


Ripple’s Discovery

Epidel™ is founded on a discovery that drugs can be designed to deliver themselves without the need for polymers or excipients. Epidel™ prodrug materials are readily manufactured into implantable forms like cylinders and microspheres. Drug dissolves from the surface of the implant via surface erosion in a highly predictable manner: dose is dictated by implant surface area; duration by implant diameter. The result is an ability to finely tune pharmacokinetics to meet the needs of a target indication with precision control of drug dosing without the bulk added by a polymer.


In the true spirit of invention, Epidel was borne out of constraint. In the mid-1990s, the Controlled Release Field was focused on conjugating drugs into polymer backbones as a way of controlling drug release. While the science was conceptually appealing, the lack of reproducible manufacturing and the complexity of a polydisperse polymeric breakdown profile limited the translation into approval products.  


In our Toronto laboratories, these constraints inspired a minimalistic approach to re-think how controlled drug delivery could be achieved. A novel prodrug approach was discovered which provided a simple, highly predictable, and tunable way to achieve sustained drug release without the use of polymers or excipients. Read more.

Our Science

No polymers. No excipients.


  • High drug loading (80%+)
  • Smaller implants, no pro-inflammatory degradation products
  • Highly tunable drug release and duration via surface erosion
  • Simple, scalable, low cost manufacturing processes


Pulled Fiber

Microparticles by emulsion

Extruded Rod

Electro sprayed

Micro particles

Medical Device Coating

Solvent Casting

Powder Coating


Validating the vision timeline


2017

Discovery that prodrugs can be formed into 3 dimensional pharmaceuticals implants without polymers or excipients


2018

Strategic focus on ophthalmology; Retinal implant POC completed; FDA PIND meeting defines 505(b)2 



2019

Dexamethasone intravitreal implant PK/PD data confirms safety, efficacy and duration; CMC Tech Transfer to experienced CDMOs



2020

Ripple spun out of IBI; $10M (seed capital + convertible debt) Licensing Agreement signed TOI; $15M Series A Financing; Glaucoma program initiated



2021

First patients treated in Ripple-1 with Dex IVT implant; Key patents granted; Glaucoma implant preclinical POC completed



2022

Ripple-1 Clinical Trial demonstrates biological effect, duration and safety of Dex IVT implant; Glaucoma implant PK/PD data confirms safety & efficacy


Partners

In October of 2022, we signed an exclusive Licensing Agreement for our lead retina product (IBE-814 IVT) for China with CS Pharmaceuticals ("CSP"), a British headquartered multinational company focused on the development and commercialization of rare disease and ophthalmology products in China.


See
Press Release.

Contact us

We are also working with a number of Pharma partners interested in evaluating our extended-release prodrug technology with their proprietary APIs. 

We are also pleased to work with the following product development partners:

About us

Our leadership team has experience in managing both small and large public and private companies through various stages of growth and financing strategies (venture capital, M&A transactions, IPOs, PIPEs). They successfully sold the surface modification business of Interface Biologics to Evonik (ETR:EVK) in 2019 and founded Ripple Therapeutics in January of 2020.


Our team is made up of a high calibre group of PhD and MSc Chemists, Engineers and Material Scientists.

News & Updates

20 Mar, 2023
Lisbon, March 20, 2023, Hovione, the specialist integrated CDMO, leader in spray drying and particle engineering, and Ripple Therapeutics, a leading ophthalmic sustained drug delivery company, have entered a strategic partnership to expand the use of Ripple's Epidel® platform beyond ophthalmic applications. The core feature of Ripple’s Epidel® technology is the ability to deliver sustained-release pharmaceuticals with surface erosion release kinetics without the use of polymers or excipients. This enables higher drug loading, smaller size implants, defined and predictable biocompatible degradation products with straightforward and scalable manufacturing processes. Surface erosion-based drug release provides a highly effective way to control dose and duration. By incorporating Ripple's Epidel® platform into its toolbox, Hovione can expand its portfolio of novel drug delivery solutions to the pharmaceutical industry. “The combination of technology synergy, innovative vision and cultural fit makes collaborating with Hovione an exciting next step in the advancement of the Epidel® platform beyond the ophthalmic field,” stated Dr. Wendy Naimark, Ripple co-founder and Chief Technology Officer. “Hovione’s expertise in controlled, sustained drug delivery, along with their experience in chemical synthesis and pharmaceutical manufacturing, makes for a great partnership.” "We are thrilled to partner with Ripple, who developed a state-of-the-art platform for sustained release," says Dr. Jean-Luc Herbeaux, Hovione's CEO. " Our shared goal is to accelerate and broaden the access to this highly innovative and enabling technology for the benefit of our pharmaceutical customers and their patients worldwide." By extending the use of the Epidel® platform beyond ocular applications, this partnership will enable the development of a diverse range of new products with optimal sustained release profiles. About Hovione: Hovione is an international company with over 60 years of experience in pharmaceutical development and manufacturing operations. As a Contract Development and Manufacturing Organization (CDMO) with a fully integrated offering of services for drug substances, drug product intermediates and drug products. The company has four FDA inspected sites in the USA, Portugal, Ireland and China and development laboratories in Lisbon, Portugal and New Jersey, USA. Hovione provides pharmaceutical customers services for the development and compliant manufacture of innovative drugs, including highly potent compounds, and customized product solutions across the entire drug life cycle. In the inhalation area, Hovione offers a complete range of services, from API, formulation development and devices. Hovione's culture is based on innovation, quality and dependability. Hovione was the first Chemical/ Pharmaceutical Company to become a Certified B Corp, is a member of Rx-360, EFCG and participates actively in industry quality improvement initiatives to lead new global industry standards. About Ripple Therapeutics: Ripple Therapeutics Corporation is a clinical stage, privately held company that is focused on ophthalmic therapeutics with controllable, sustainable drug delivery. The core feature of Ripple’s Epidel™ technology is the ability to engineer sustained-release pharmaceuticals with surface erosion release kinetics without the use of polymers or excipients. Ripple’s novel therapeutics provide for better outcomes for patients, easier management of care for physicians and lower costs for payors. Ripple has a full product pipeline in development. www.rippletherapeutics.com For more information, please visit www .hovione.com or contact: Vanessa Romeu | Communications Director | vromeu@hovione.com |Tel: +351 21 982 9000 Or visit www.rippletherapeutics.com or contact: Julie Fotheringham | V.P. Marketing, People & Culture | 416-951-7988| jfotheringham@rippletherapeutics.com
25 Jan, 2023
TORONTO, ON, CANADA / JANUARY 24, 2023 - Ripple Therapeutics is proud to announce that our organization has been named on the 2023 Best Workplaces for Start-ups. Ripple received this honour after a thorough and independent analysis conducted by Great Place to Work®. The list is based on direct feedback from employees of the hundreds of organizations that were surveyed by Great Place to Work®. To be eligible for this list, organizations must be Great Place to Work- Certified™ and have exceptionally high scores from employees on the Trust Index survey. “At Ripple, we are intentional about investing in people”, commented Tom Reeves, President & CEO. “Our core values emphasize that we care, we collaborate, and we have fun while persevering to find innovative solutions to complex problems. As such, it’s great to receive this independent third-party validation that we are a great place to work.” About Ripple Therapeutics Ripple Therapeutics Corporation is a clinical stage, privately held company that is focused on ophthalmic therapeutics with controllable, sustainable drug delivery. The core feature of Ripple’s Epidel™ technology is the ability to engineer sustained-release pharmaceuticals with zero-order release kinetics without the use of polymers or excipients. Ripple has a full product pipeline in development. www.rippletherapeutics.com About Great Place to Work® Great Place to Work is the global authority on high-trust, high-performance workplace cultures. Through proprietary assessment tools, advisory services, and certification programs, Great Place to Work recognizes Canada’s Best Workplaces in a series of national lists including those published by The Globe & Mail (Canada) and Fortune magazine (USA). Great Place to Work provides the benchmarks, framework, and expertise needed to create, sustain, and recognize outstanding workplace cultures. Visit us at www.greatplacetowork.ca or find us on Twitter at @GPTW_Canada. Media Contact Julie Fotheringham, V.P. Marketing, People & Culture M: 416-951-7988 E: jfotheringham@rippletherapeutics.com
29 Nov, 2022
TORONTO, ON, CANADA / NOVEMBER 29, 2022 - Ripple Therapeutics Corporation, a clinical stage ophthalmic therapeutics company, today announced Jonathan Talamo, M.D., currently a member of its Board, has been appointed as the new Chair of its Board of Directors. Dr. Talamo is internationally known as an experienced surgeon and thought leader in ophthalmology. Following 25 years in clinical practice, Dr. Talamo served as the Chief Medical Officer at Ocular Therapeutix, an ophthalmic drug delivery company, where he oversaw development programs in multiple therapeutic areas, including post–cataract surgery inflammation, dry eye, allergy, glaucoma and retinal vascular diseases. Most recently, he served as Chief Medical Officer and Worldwide VP of Clinical and Medical Affairs at Johnson and Johnson Vision. While at J&J, Dr. Talamo helped lead the integration of Abbott Medical Optics as well as the development and launch of numerous innovative products. “It’s an exciting time at Ripple Therapeutics, with licensing agreements in place and a clinical trial well underway for IBE-814 IVT (treating DME and RVO) and progress towards the clinic with RTC-1119 (treating glaucoma)”, commented Dr. Talamo. “I’m looking forward to working even more closely with the Ripple Board and team to bring important, proprietary extended-release ophthalmic therapeutics to market that address significant unmet needs for patients and clinicians.” “With his clinical experience as an ophthalmologist and industry experience with both large and small companies, Jon has already brought tremendous insight to our Board”, stated Tom Reeves, President and CEO, Ripple Therapeutics. “Now as Chair, we look forward to his leadership as we work to realize our vision of developing novel therapeutics that provide better outcomes for patients, easier management of care for physicians and lower costs for payors.” About Ripple Therapeutics Ripple Therapeutics Corporation is a clinical stage, privately held company that is focused on ophthalmic therapeutics with controllable, sustainable drug delivery. The core feature of Ripple’s Epidel™ technology is the ability to engineer sustained-release pharmaceuticals with zero-order release kinetics without the use of polymers or excipients. Ripple’s novel therapeutics provide for better outcomes for patients, easier management of care for physicians and lower costs for payors. Ripple has a full product pipeline in development. www.rippletherapeutics.com Media Contact: Julie Fotheringham, V.P. Marketing, People & Culture M: 416-951-7988 E: jfotheringham@rippletherapeutics.com 
Show More
Share by: